Free Trial

Cellectis (CLLS) Competitors

Cellectis logo
$2.67 -0.14 (-4.98%)
Closing price 04:00 PM Eastern
Extended Trading
$2.64 -0.03 (-1.27%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLLS vs. TBPH, SAGE, PRME, RZLT, UPXI, SLDB, KURA, ORKA, TERN, and OPT

Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Prime Medicine (PRME), Rezolute (RZLT), Upexi (UPXI), Solid Biosciences (SLDB), Kura Oncology (KURA), Oruka Therapeutics (ORKA), Terns Pharmaceuticals (TERN), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry.

Cellectis vs. Its Competitors

Theravance Biopharma (NASDAQ:TBPH) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Theravance Biopharma has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500.

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma has a net margin of -89.38% compared to Cellectis' net margin of -114.82%. Theravance Biopharma's return on equity of -32.37% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma-89.38% -32.37% -16.48%
Cellectis -114.82%-62.55%-21.19%

Theravance Biopharma presently has a consensus target price of $16.60, suggesting a potential upside of 50.10%. Cellectis has a consensus target price of $4.00, suggesting a potential upside of 49.31%. Given Theravance Biopharma's higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Cellectis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.67
Cellectis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cellectis has lower revenue, but higher earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$64.38M8.59-$56.42M-$1.18-9.37
Cellectis$49.22M3.03-$36.76M-$0.86-3.12

In the previous week, Cellectis had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for Cellectis and 3 mentions for Theravance Biopharma. Cellectis' average media sentiment score of 0.71 beat Theravance Biopharma's score of 0.47 indicating that Cellectis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cellectis
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Theravance Biopharma beats Cellectis on 9 of the 17 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLLS vs. The Competition

MetricCellectisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$148.90M$3.04B$5.59B$9.53B
Dividend YieldN/A2.39%4.71%4.03%
P/E Ratio-3.1221.2227.9619.93
Price / Sales3.03200.39389.5465.88
Price / CashN/A42.5736.3258.75
Price / Book1.148.268.375.77
Net Income-$36.76M-$55.06M$3.25B$259.10M
7 Day Performance14.98%-3.99%-2.50%-3.41%
1 Month Performance75.67%13.86%7.98%8.53%
1 Year Performance22.89%4.02%34.65%15.75%

Cellectis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLLS
Cellectis
2.8838 of 5 stars
$2.67
-5.0%
$4.00
+49.8%
+27.1%$148.40M$49.22M-3.10290News Coverage
Upcoming Earnings
TBPH
Theravance Biopharma
1.7343 of 5 stars
$11.06
+0.3%
$16.60
+50.1%
+9.1%$551.52M$64.38M0.00110Upcoming Earnings
SAGE
Sage Therapeutics
3.4056 of 5 stars
$8.78
-0.2%
$8.02
-8.7%
-19.5%$551.06M$41.24M0.00690Positive News
PRME
Prime Medicine
3.8423 of 5 stars
$4.09
-2.9%
$9.25
+126.2%
-31.2%$550.09M$3.85M-2.00234News Coverage
RZLT
Rezolute
2.3362 of 5 stars
$6.38
+1.3%
$11.83
+85.5%
+35.1%$548.08MN/A0.0040Analyst Revision
UPXI
Upexi
2.6983 of 5 stars
$5.88
-3.8%
$16.00
+172.1%
-24.6%$546M$26M0.00130News Coverage
Positive News
Options Volume
Gap Down
SLDB
Solid Biosciences
3.2939 of 5 stars
$7.02
+0.3%
$15.10
+115.1%
-25.6%$542.61M$8.09M0.00100
KURA
Kura Oncology
4.5141 of 5 stars
$6.20
-0.5%
$24.50
+295.2%
-69.5%$539.36M$53.88M0.00130Positive News
Upcoming Earnings
ORKA
Oruka Therapeutics
2.7026 of 5 stars
$14.01
-1.7%
$40.38
+188.2%
N/A$533.53MN/A0.00N/A
TERN
Terns Pharmaceuticals
3.7629 of 5 stars
$5.95
-1.7%
$15.63
+162.6%
-31.0%$528.39MN/A0.0040Upcoming Earnings
OPT
Opthea
0.3553 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+51.6%$524.84M$120K0.008Positive News
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:CLLS) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners